Showing results (761-770 of 3,472) with videos related to
Sort By:
Pageof 348
Clinical Pharmacokinetics|October 27, 2012
Pharmacokinetics of non-intravenous formulations of fentanylJörn Lötsch, Carmen Walter, Michael J Parnham, et al.Clinical Pharmacokinetics|September 29, 2012
Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantationTroels K Bergmann, Katherine A Barraclough, Katie J Lee, et al.Clinical Pharmacokinetics|September 29, 2012
Pharmacokinetics of aliskiren in patients with end-stage renal disease undergoing haemodialysisDmytro Khadzhynov, Torsten Slowinski, Ina Lieker, et al.Clinical Pharmacokinetics|September 29, 2012
Pharmacokinetics and clinical efficacy of phenobarbital in asphyxiated newborns treated with hypothermia: a thermopharmacological approachM P H van den Broek, F Groenendaal, M C Toet, et al.Clinical Pharmacokinetics|September 29, 2012
A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjectsRandy Dockens, Jun-Sheng Wang, Lorna Castaneda, et al.Clinical Pharmacokinetics|July 30, 2020
Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial AgentsMarkus Zeitlinger, Birgit C P Koch, Roger Bruggemann, et al.Clinical Pharmacokinetics|August 12, 2020
Simple Approach to Accurately Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies after Subcutaneous Injection in HumansKenta Haraya, Tatsuhiko TachibanaClinical Pharmacokinetics|January 24, 2014
Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia BLei Diao, Shuanglian Li, Thomas Ludden, et al.Clinical Pharmacokinetics|July 2, 2014
Why dried blood spots are an ideal tool for CYP1A2 phenotypingPieter M M De Kesel, Willy E Lambert, Christophe P StoveClinical Pharmacokinetics|July 4, 2014
Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoringManjunath P Pai, Piergiorgio Cojutti, Federico PeaPageof 348